<code id='FF77E9A21E'></code><style id='FF77E9A21E'></style>
      • <acronym id='FF77E9A21E'></acronym>
      <center id='FF77E9A21E'><center id='FF77E9A21E'><tfoot id='FF77E9A21E'></tfoot></center><abbr id='FF77E9A21E'><dir id='FF77E9A21E'><tfoot id='FF77E9A21E'></tfoot><noframes id='FF77E9A21E'>
      • <optgroup id='FF77E9A21E'><strike id='FF77E9A21E'><sup id='FF77E9A21E'></sup></strike><code id='FF77E9A21E'></code></optgroup>
        5. <b id='FF77E9A21E'><label id='FF77E9A21E'><select id='FF77E9A21E'><dt id='FF77E9A21E'><span id='FF77E9A21E'></span></dt></select></label></b><u id='FF77E9A21E'></u>
          <i id='FF77E9A21E'><strike id='FF77E9A21E'><tt id='FF77E9A21E'><pre id='FF77E9A21E'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-09-29 20:22:34 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：49931
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          FDA early review: GLP
                                
                            
          Next article：  
                                      
                                          United colonoscopy coverage change 'may cost lives,' doctors say
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles